亚洲地区非酒精性脂肪性肝病的流行病学特点

李婕

doi:10.3969/j.issn.1001-5256.2018.12.006

亚洲地区非酒精性脂肪性肝病的流行病学特点

DOI: 10.3969/j.issn.1001-5256.2018.12.006

李婕

基金项目:

国家“十三五”科技重大专项项目(2018ZX10302206-001-006)；山东省自然科学基金(ZR2017MH102)；济南市科技发展计划(201704109)；

详细信息

中图分类号: R575;R181.3
计量
- 文章访问数: 1678
- HTML全文浏览量: 35
- PDF下载量: 471
- 被引次数: 0
出版历程
- 出版日期: 2018-12-20

Epidemiology characteristics of nonalcoholic fatty liver disease in Asia

Li Jie

Research funding:

摘要

摘要: 随着亚洲国家工业化程度的提高,以及生活方式和饮食结构的改变,非酒精性脂肪性肝病(NAFLD)的患病率不断攀升。但亚洲人口众多且分布不均,经济文化水平、生活方式等存在明显的地域差异,导致亚洲不同地区NAFLD流行病学情况差异较大。了解NAFLD的发病率、患病率、病死率以及相关的危险因素等流行病学特点,可为研究该疾病的进展和相应的公共卫生防控策略提供依据。
- 非酒精性脂肪性肝病 /
- 亚洲 /
- 流行病学
Abstract: The prevalence rate of nonalcoholic fatty liver disease (NAFLD) is constantly increasing due to the increase in the degree of industrialization in Asian countries and the change in lifestyle and dietary structure. Asia has a large population with uneven distribution and marked regional disparities in economic and education levels and lifestyle, which results in the great difference in the epidemiology of NAFLD across different regions in Asia. An understanding of epidemiological features of NAFLD, including incidence, prevalence, and mortality rates and related risk factors can provide a basis for the research on disease progression and related prevention and control strategies.
- non-alcoholic fatty liver disease /
- Asia /
- epidemiology

HTML全文

参考文献(34)

[1] NOUREDDIN M, VIPANI A, BRESEE C, et al. NASH leading cause of liver transplant in women:Updated analysis of indications for liver transplant and ethnic and gender variances[J]. Am J Gastroenterol, 2018.[Epub ahead of print]

[2] CHITTURI S, FARRELL GC, HASHIMOTO E, et al. Non-alcoholic fatty liver disease in the Asia-Pacific region:Definitions and overview of proposed guidelines[J]. J Gastroenterol Hepatol, 2007, 22 (6) :778-787.

[3] WONG VW, CHAN WK, CHITTURI S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines2017-Part 1:Definition, risk factors and assessment[J]. J Gastroenterol Hepatol, 2018, 33 (1) :70-85.

[4] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64 (1) :73-84.

[5] SETO WK, YUEN MF. Nonalcoholic fatty liver disease in Asia:Emerging perspectives[J]. J Gastroenterol, 2017, 52 (2) :164-174.

[6] PERUMPAIL BJ, KHAN MA, YOO ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease[J].World J Gastroenterol, 2017, 23 (47) :8263-8276.

[7] FARRELL GC, WONG VW, CHITTURI S. NAFLD in Asia-as common and important as in the West[J]. Nat Rev Gastroenterol Hepatol, 2013, 10 (5) :307-318.

[8] SINGH S, KUFTINEC GN, SARKAR S. Non-alcoholic fatty liver disease in South Asians:A review of the literature[J]. J Clin Transl Hepatol, 2017, 5 (1) :76-81.

[9] PATI GK, SINGH SP. Nonalcoholic fatty liver disease in South Asia[J]. Euroasian J Hepatogastroenterol, 2016, 6 (2) :154-162.

[10] KARIMI-SARI H, MOUSAVI-NAEINI SM, KHONCHE A.Comments on prevalence of non-alcoholic fatty liver disease and its related factors in Iran[J]. Int J Organ Transplant Med, 2017, 8 (1) :52-53.

[11] GOH SC, HO ELM, GOH KL. Prevalence and risk factors of nonalcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia[J]. Hepatol Int, 2013, 7 (2) :548-554.

[12] JIE L, BIYAO Z, HIDEKI F, et al. Prevalence of non-alcoholic fatty liver disease (NAFLD) in Asia:A systematic review and meta-analysisof 195 studies and 1, 753, 168 subjects from 13 countries[C]. The 27th Asian Pacific Association for the Study of the Liver, 2018.

[13] FAN JG, KIM SU, WONG VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67 (4) :862-873.

[14] VANWAGNER LB, ARMSTRONG MJ. Lean NAFLD:A not so benign condition?[J]. Hepatol Commun, 2018, 2 (1) :5-8.

[15] FUNG J, LEE CK, CHAN M, et al. High prevalence of non-alcoholic fatty liver disease in the Chinese-results from the Hong Kong liver health census[J]. Liver Int, 2015, 35 (2) :542-549.

[16] LI Z, XUE J, CHEN P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China:A meta-analysis of published studies[J]. J Gastroenterol Hepatol, 2014, 29 (1) :42-51.

[17] ESTES C, ANSTEE QM, TERESA ARIAS-LOSTE M, et al.Modeling NAFLD disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69 (4) :896-904.

[18] YOUNOSSI Z, TACKE F, ARRESE M, et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Hepatology, 2018.[Epub ahead of print]

[19] FAZEL Y, KOENIG AB, SAYINER M, et al. Epidemiology and natural history of non-alcoholic fatty liver disease[J]. Metabolism, 2016, 65 (8) :1017-1025.

[20] NIRIELLA MA, PATHMESWARAN A, DE SILVA ST, et al. Incidence and risk factors for non-alcoholic fatty liver disease:A 7-year follow-up study among urban, adult Sri Lankans[J]. Liver Int, 2017, 37 (11) :1715-1722.

[21] ZHANG T, ZHANG C, ZHANG Y, et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population:A prospective cohort study[J]. Atherosclerosis, 2015, 240 (1) :144-148.

[22] WU J, HE S, XU H, et al. Non-alcoholic fatty liver disease incidence, remission and risk factors among a general Chinese population with a 6-year follow-up[J]. Sci Rep, 2018, 8 (1) :7557.

[23] DICKSON I. NAFLD:Increased familial risk of fibrosis in NAFLD[J].Nat Rev Gastroenterol Hepatol, 2017, 14 (8) :450.

[24] NAKAHARA T, HYOGO H, YONEDA M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients[J]. J Gastroenterol, 2014, 49 (11) :1477-1484.

[25] MIYAKE T, KUMAGI T, HIROOKA M, et al. Significance of exercise in nonalcoholic fatty liver disease in men:A communitybased large cross-sectional study[J]. J Gastroenterol, 2015, 50 (2) :230-237.

[26] TAO Y, GU H, WU J, et al. Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects[J]. Endocr Res, 2015, 40 (2) :74-78.

[27] SHEN J, WONG GL, CHAN HL, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome[J]. Aliment Pharmacol Ther, 2014, 39 (5) :532-539.

[28] FRACANZANI AL, PETTA S, LOMBARDI R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity[J]. Clin Gastroenterol Hepatol, 2017, 15 (10) :1604-1611, e1601.

[29] MASARONE M, FEDERICO A, ABENAVOLI L, et al. Non alcoholic fatty liver:Epidemiology and natural history[J]. Rev Recent Clin Trials, 2014, 9 (3) :126-133.

[30] MARCUCCILLI M, CHONCHOL M. NAFLD and chronic kidney disease[J]. Int J Mol Sci, 2016, 17 (4) :562.

[31] SINN DH, KANG D, JANG HR, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease:A cohort study[J]. J Hepatol, 2017, 67 (6) :1274-1280.

[32] LEE DY, PARK JK, HUR KY, et al. Association between nonalcoholic fatty liver disease and bone mineral density in postmenopausal women[J]. Climacteric, 2018, 21 (5) :498-501.

[33] SHEN F, ZHENG RD, SHI JP, et al. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease[J]. Liver Int, 2015, 35 (11) :2392-2400.

[34] FLORES A, MARRERO JA. Emerging trends in hepatocellular carcinoma:Focus on diagnosis and therapeutics[J]. Clin Med Insights Oncol, 2014, 8:71-76.

施引文献

资源附件(0)

访问统计